Key facts
- Slate Medicines’s last known valuation is $176.0M (Feb 2026).
- It has raised $133.0M across 1 recorded rounds; the latest was Early Stage VC ($10.0M) in Feb 2026.
- Notable investors include RA Capital Management, Foresite Capital, Forbion.
- Slate Medicines has filed 1 Form D with the SEC, most recently Mar 2026 ($10.0M sold to 6 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Slate Medicines
Create free account
No card required
Funding rounds
1 roundsAbout Slate Medicines
Operator of a biotechnology company intended to develop next-generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Website
- slatemedicines.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Slate Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Slate Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Slate Medicines in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.